A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer.
Boland PM, Lenz HJ, Ciombor KK, Florou V, Pishvaian MJ, Cusnir M, Cohen D, Guo JY, Tang M, Rajagopalan P, Wiley SE, Ghalie RG, Hochster HS.
Boland PM, et al. Among authors: cohen d.
Invest New Drugs. 2024 Dec 27. doi: 10.1007/s10637-024-01489-1. Online ahead of print.
Invest New Drugs. 2024.
PMID: 39725778